Cybin to participate at the 2023 milken institute future of health summit

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today announced that doug drysdale, cybin's chief executive officer, will be speaking at the 2023 milken institute future of health summit on a panel entitled “revolutionizing mental health care through innovation.” “it is an honor to be part of.
CYBN Ratings Summary
CYBN Quant Ranking